Agilent secures CE-IVD Mark for cervical cancer test

By LabPulse.com staff writers

May 11, 2022 -- Agilent Technologies has secured the CE-IVD Mark in Europe for its companion diagnostic test for identifying cervical cancer patients eligible for treatment with Merck's Keytruda (pembrolizumab) immunotherapy.

PD-L1 is an antibody expressed by cervical cancer tumors and is a key biomarker for predicting response to anti-PD-L1 therapies like Keytruda, according to Agilent. The company's PD-L1 IHC 22C3 pharmDx companion diagnostic identifies cervical cancer patients with a PD-L1 combined positive score of one or more, which indicates that they could benefit from treatment with Keytruda, the company said.

Agilent touts study of FTIR-based saliva COVID test
Agilent Technologies is highlighting a recent study that shows its Cary 630 Fourier transform infrared (FTIR) Spectrometer may be a simple, robust method...
Agilent acquires Virtual Control's lab AI technology
Agilent has acquired artificial intelligence (AI) technology developed by Virtual Control, a software development company for laboratory solutions. Agilent...
Agilent highlights automation platforms at SLAS 2022
Agilent Technologies highlighted the company's integrated automation platforms, including a live cell analysis system at the Society for Laboratory Automation...
Agilent receives FDA approval for breast cancer assay
Agilent Technologies has received approval from the U.S. Food and Drug Administration (FDA) for its Ki-67 IHC MIB-1 pharmDx assay. The assay can help...
Agilent enters digital pathology with Visiopharm deal
Agilent Technologies and Visiopharm have signed a worldwide distribution agreement that allows Agilent to co-market Visiopharm's portfolio of digital...

Copyright © 2022 LabPulse.com

Last Updated bc 5/12/2022 6:38:27 AM